Treatment intensification to maximize disease control and reduced intensity approaches to minimize the risk of late sequelae have been evaluated in newly diagnosed Hodgkin lymphoma. The influence of these interventions on the risk of secondary malignant neoplasms, progression-free survival and overall survival is reported in the meta-analysis herein, based on individual patient data from 9498 patients treated within 16 randomized controlled trials for newly diagnosed Hodgkin lymphoma between 1984 and 2007. Secondary malignant neoplasms were meta-analyzed using Peto’s method as time-to-event outcomes. For progression-free and overall survival, hazard ratios derived from each trial using Cox regression were combined by inverse-variance weighting. Five study questions (combined-modality treatment vs. chemotherapy alone; more extended vs. involved-field radiotherapy; radiation at higher doses vs. radiation at 20 Gy; more vs. fewer cycles of the same chemotherapy protocol; standard-dose chemotherapy vs. intensified chemotherapy) were investigated. After a median follow-up of 7.4 years, dose-intensified chemotherapy resulted in better progression-free survival rates (P=0.007) as compared with standard-dose chemotherapy, but was associated with an increased risk of therapy-related acute myeloid leukemia/myelodysplastic syndromes (P=0.0028). No progression-free or overall survival differences were observed between combined-modality treatment and chemotherapy alone, but more secondary malignant neoplasms were seen after combined-modality treatment (P=0.010). For the remaining three study questions, outcomes and secondary malignancy rates did not differ significantly between treatment strategies. The results of this meta-analysis help to weigh up efficacy and secondary malignancy risk for the choice of first-line treatment for Hodgkin lymphoma patients. However, final conclusions regarding secondary solid tumors require longer follow-up.

Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials / Eichenauer, Dennis A.; Becker, Ingrid; Monsef, Ina; Chadwick, Nicholas; De Sanctis, Vitaliana; Federico, Massimo; Fortpied, Catherine; Gianni, Alessandro M.; Henry-Amar, Michel; Hoskin, Peter; Johnson, Peter; Luminari, Stefano; Bellei, Monica; Pulsoni, Alessandro; Sydes, Matthew R.; Valagussa, Pinuccia; Viviani, Simonetta; Engert, Andreas; Franklin, Jeremy. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 102:10(2017), pp. 1748-1757. [10.3324/haematol.2017.167478]

Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials

Federico, Massimo
Writing – Original Draft Preparation
;
Luminari, Stefano
Writing – Original Draft Preparation
;
Bellei, Monica
Writing – Review & Editing
;
2017

Abstract

Treatment intensification to maximize disease control and reduced intensity approaches to minimize the risk of late sequelae have been evaluated in newly diagnosed Hodgkin lymphoma. The influence of these interventions on the risk of secondary malignant neoplasms, progression-free survival and overall survival is reported in the meta-analysis herein, based on individual patient data from 9498 patients treated within 16 randomized controlled trials for newly diagnosed Hodgkin lymphoma between 1984 and 2007. Secondary malignant neoplasms were meta-analyzed using Peto’s method as time-to-event outcomes. For progression-free and overall survival, hazard ratios derived from each trial using Cox regression were combined by inverse-variance weighting. Five study questions (combined-modality treatment vs. chemotherapy alone; more extended vs. involved-field radiotherapy; radiation at higher doses vs. radiation at 20 Gy; more vs. fewer cycles of the same chemotherapy protocol; standard-dose chemotherapy vs. intensified chemotherapy) were investigated. After a median follow-up of 7.4 years, dose-intensified chemotherapy resulted in better progression-free survival rates (P=0.007) as compared with standard-dose chemotherapy, but was associated with an increased risk of therapy-related acute myeloid leukemia/myelodysplastic syndromes (P=0.0028). No progression-free or overall survival differences were observed between combined-modality treatment and chemotherapy alone, but more secondary malignant neoplasms were seen after combined-modality treatment (P=0.010). For the remaining three study questions, outcomes and secondary malignancy rates did not differ significantly between treatment strategies. The results of this meta-analysis help to weigh up efficacy and secondary malignancy risk for the choice of first-line treatment for Hodgkin lymphoma patients. However, final conclusions regarding secondary solid tumors require longer follow-up.
2017
14-set-2017
102
10
1748
1757
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials / Eichenauer, Dennis A.; Becker, Ingrid; Monsef, Ina; Chadwick, Nicholas; De Sanctis, Vitaliana; Federico, Massimo; Fortpied, Catherine; Gianni, Alessandro M.; Henry-Amar, Michel; Hoskin, Peter; Johnson, Peter; Luminari, Stefano; Bellei, Monica; Pulsoni, Alessandro; Sydes, Matthew R.; Valagussa, Pinuccia; Viviani, Simonetta; Engert, Andreas; Franklin, Jeremy. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 102:10(2017), pp. 1748-1757. [10.3324/haematol.2017.167478]
Eichenauer, Dennis A.; Becker, Ingrid; Monsef, Ina; Chadwick, Nicholas; De Sanctis, Vitaliana; Federico, Massimo; Fortpied, Catherine; Gianni, Alessandro M.; Henry-Amar, Michel; Hoskin, Peter; Johnson, Peter; Luminari, Stefano; Bellei, Monica; Pulsoni, Alessandro; Sydes, Matthew R.; Valagussa, Pinuccia; Viviani, Simonetta; Engert, Andreas; Franklin, Jeremy
File in questo prodotto:
File Dimensione Formato  
10.3324@haematol.2017.167478.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 865.73 kB
Formato Adobe PDF
865.73 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1152784
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 35
social impact